Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
DEPOMED, INC. v. PURDUE PHARMA L.P. et al
Case Number:
3:13-cv-00571
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 30, 2018
Purdue Ends OxyContin Patent Suit With $62M Payout
Purdue Pharma LP has agreed to pay Assertio Therapeutics Inc., formerly known as Depomed Inc., $62 million in cash to settle claims in New Jersey federal court that Purdue's blockbuster opioid painkiller OxyContin infringed two of Assertio's patents.
-
November 26, 2013
Purdue's Bid To Split OxyContin Patent Suit Gets Rejected
A New Jersey federal judge on Tuesday declined to split into two phases any such trial in Depomed Inc.'s suit alleging Purdue Pharma LP's pain reliever OxyContin infringed on three of its patents for extended-release drug technology, saying bifurcation isn't warranted.